Latest Insider Transactions at Incyte Corp (INCY)
This section provides a real-time view of insider transactions for Incyte Corp (INCY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of INCYTE CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of INCYTE CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 25
2021
|
Vijay K Iyengar EVP, GMAPPS |
SELL
Open market or private sale
|
Direct |
5,116
-8.42%
|
$506,484
$99.0 P/Share
|
|
Jan 25
2021
|
Vijay K Iyengar EVP, GMAPPS |
BUY
Exercise of conversion of derivative security
|
Direct |
4,116
+11.63%
|
$296,352
$72.86 P/Share
|
|
Jan 25
2021
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,795
-3.07%
|
$379,500
$100.0 P/Share
|
|
Jan 25
2021
|
Steven H Stein EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,795
+2.98%
|
$258,060
$68.62 P/Share
|
|
Jan 25
2021
|
Yao Wenqing EVP, Head of Discovery Chem |
SELL
Open market or private sale
|
Direct |
21,545
-6.64%
|
$2,154,500
$100.0 P/Share
|
|
Jan 25
2021
|
Yao Wenqing EVP, Head of Discovery Chem |
BUY
Exercise of conversion of derivative security
|
Direct |
21,545
+5.97%
|
$1,572,785
$73.21 P/Share
|
|
Jan 19
2021
|
Jonathan Elliott Dickinson EVP, General Manager, Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
174
-0.64%
|
$16,182
$93.96 P/Share
|
|
Jan 19
2021
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
174
-0.26%
|
$16,182
$93.96 P/Share
|
|
Jan 15
2021
|
Jonathan Elliott Dickinson EVP, General Manager, Europe |
BUY
Grant, award, or other acquisition
|
Direct |
5,761
+17.38%
|
-
|
|
Jan 15
2021
|
Paul Trower Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,032
+12.42%
|
-
|
|
Jan 15
2021
|
Michael James Morrissey EVP, Head of Tech. Operations |
BUY
Grant, award, or other acquisition
|
Direct |
17,283
+12.09%
|
-
|
|
Jan 15
2021
|
Barry P Flannelly EVP & General Manager US |
BUY
Grant, award, or other acquisition
|
Direct |
11,522
+17.93%
|
-
|
|
Jan 15
2021
|
Steven H Stein EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,044
+16.14%
|
-
|
|
Jan 15
2021
|
Yao Wenqing EVP, Head of Discovery Chem |
BUY
Grant, award, or other acquisition
|
Direct |
11,522
+7.42%
|
-
|
|
Jan 15
2021
|
Christiana Stamoulis EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,522
+25.41%
|
-
|
|
Jan 11
2021
|
Maria E Pasquale EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
127
+0.42%
|
$8,255
$65.36 P/Share
|
|
Jan 04
2021
|
Jonathan Elliott Dickinson EVP, General Manager, Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
136
-0.62%
|
$11,696
$86.45 P/Share
|
|
Jan 04
2021
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
136
-0.28%
|
$11,696
$86.45 P/Share
|
|
Dec 31
2020
|
Wendy L Dixon Director |
BUY
Grant, award, or other acquisition
|
Direct |
213
+1.43%
|
$18,318
$86.98 P/Share
|
|
Dec 31
2020
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
275
+2.99%
|
$23,650
$86.98 P/Share
|
|
Dec 31
2020
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
237
+4.31%
|
$20,382
$86.98 P/Share
|
|
Dec 31
2020
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
281
+5.53%
|
$24,166
$86.98 P/Share
|
|
Dec 31
2020
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
207
+7.67%
|
$17,802
$86.98 P/Share
|
|
Dec 31
2020
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
686
+0.01%
|
-
|
|
Dec 11
2020
|
Maria E Pasquale EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
128
+0.43%
|
$8,320
$65.36 P/Share
|
|
Dec 10
2020
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
720
-2.46%
|
$59,040
$82.05 P/Share
|
|
Nov 16
2020
|
Dashyant Dhanak EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,232
+4.04%
|
-
|
|
Nov 16
2020
|
Barry P Flannelly EVP & General Manager US |
BUY
Grant, award, or other acquisition
|
Direct |
1,232
+2.9%
|
-
|
|
Nov 16
2020
|
Herve Hoppenot Chairman / CEO |
BUY
Grant, award, or other acquisition
|
Direct |
7,225
+2.59%
|
-
|
|
Nov 16
2020
|
Vijay K Iyengar EVP, GMAPPS |
BUY
Grant, award, or other acquisition
|
Direct |
1,232
+4.34%
|
-
|
|
Nov 16
2020
|
Maria E Pasquale EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
1,232
+3.97%
|
-
|
|
Nov 16
2020
|
Christiana Stamoulis EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,232
+5.24%
|
-
|
|
Nov 16
2020
|
Steven H Stein EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,232
+1.26%
|
-
|
|
Nov 16
2020
|
Paula J Swain EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
1,232
+2.23%
|
-
|
|
Nov 16
2020
|
Yao Wenqing EVP, Head of Discovery Chem |
BUY
Grant, award, or other acquisition
|
Direct |
1,232
+0.78%
|
-
|
|
Nov 12
2020
|
Maria E Pasquale EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
127
+0.44%
|
$8,255
$65.36 P/Share
|
|
Nov 10
2020
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
798
-8.45%
|
$66,234
$83.0 P/Share
|
|
Nov 06
2020
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
961
-3.32%
|
$81,685
$85.17 P/Share
|
|
Nov 06
2020
|
Dashyant Dhanak EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
961
+3.21%
|
$62,465
$65.42 P/Share
|
|
Nov 02
2020
|
Barry P Flannelly EVP & General Manager US |
SELL
Open market or private sale
|
Direct |
20,000
-33.34%
|
$1,720,000
$86.6 P/Share
|
|
Nov 02
2020
|
Barry P Flannelly EVP & General Manager US |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+25.01%
|
$960,000
$48.44 P/Share
|
|
Oct 12
2020
|
Maria E Pasquale EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
128
+0.45%
|
$8,320
$65.36 P/Share
|
|
Oct 09
2020
|
Maria E Pasquale EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
1,423
-4.78%
|
$135,185
$95.0 P/Share
|
|
Oct 09
2020
|
Maria E Pasquale EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,423
+4.56%
|
$96,764
$68.62 P/Share
|
|
Oct 06
2020
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
961
-3.32%
|
$87,451
$91.97 P/Share
|
|
Oct 06
2020
|
Dashyant Dhanak EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
961
+3.21%
|
$62,465
$65.42 P/Share
|
|
Sep 30
2020
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
634
+0.01%
|
-
|
|
Sep 30
2020
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
254
+2.62%
|
$22,606
$89.74 P/Share
|
|
Sep 30
2020
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
260
+5.45%
|
$23,140
$89.74 P/Share
|
|
Sep 30
2020
|
Wendy L Dixon Director |
BUY
Grant, award, or other acquisition
|
Direct |
197
+1.35%
|
$17,533
$89.74 P/Share
|